摘要
目的评价血脂康胶囊治疗高尿酸血症的疗效和安全性。方法采用随机、双盲、安慰剂、对照的设计,将80例高尿酸血症患者随机分为两组,试验组和对照组各40例,进行治疗和比较,疗程为28d。结果共有75例完成了试验(试验组38例,对照组37例)。与用药前相比,试验组的尿酸、黄嘌呤氧化酶、空腹血浆胰岛素、胰岛素抵抗指数、三酰甘油、胆固醇、脂蛋白、超敏C反应蛋白、内皮素、尿β2微球蛋白下降和高密度脂蛋白升高均有统计学意义。试验过程中两组均未出现不良反应。结论血脂康胶囊治疗高尿酸血症具有很好的疗效和安全性。
Objective To assess the efficacy of Xuezhikang capsule on hyperuricacidemia and its safety. The study was designed as a random, double-blind placebo controlled clinical trial. 80 hyperuricacidemia patients were divided randomly into test group and control group （40 in test group and 40 in control group）. The course of treatment was 28 days. Results 75 patients finished the trial （38 in test group and 37 in control group）. After 28 days of treatment, the differences in reduction of UA, XOD, FINs, Homa-IR, TC, TG, Lp, CRP, ET, β2-MG and elevation of HDL of the test group were statistic significance. No side effect was found in the trial. Conclusion Xuezhikang capsule has good clinical effect and safety in the treatment of hyperuricacidemia.
出处
《中国中医药信息杂志》
CAS
CSCD
2006年第8期6-8,共3页
Chinese Journal of Information on Traditional Chinese Medicine
基金
北京北大维信生物科技有限公司全力资助
关键词
血脂康胶囊
高尿酸血症
随机双盲试验
Xuezhikang capsule
hyperuricacidemia
randomized double-blind clinical trial
